De Wit 1993.

Methods	Pilot study conducted in Belgium Dates of enrolment not reported. Loss to follow up: Stat dose ‐ 4/28 (14%) Daily dose ‐ 1/28 (4%) Analysis: no ITT
Participants	Eligibility criteria: AIDS/ARC patients, 18 years and older, oropharyngeal candidiasis confirmed by culture Exclusion criteria: esophageal Candidiasis diagnosis confirmed by culture 56 patients fluconazole stat ‐ 28 fluconazole daily ‐ 28
Interventions	50mg fluconazole once daily for 7 days 150mg fluconazole as a single dose Treatment duration: 7 days , monitored 26 patients (13/group) for 2 weeks after treatment
Outcomes	Clinical cure Mycological cure Relapse Adverse events: Nil reported.
Notes	Ethics: nil reported Author contacted via email: response 29/10/2004
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Method of allocation sequence generation not specified.
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	High risk	No blinding used.
Incomplete outcome data addressed? All outcomes	High risk	No reasons given for loss to follow‐up